Biography
Dr. Kurzrock is a board-certified medical oncologist and a renowned expert in precision medicine. She is known for developing one of the largest and best known Phase I clinical trial programs in the United States while at MD Anderson Cancer Center in Texas. Dr. Kurzrock established the UCSD’s Center for Personalized Cancer Therapy at the Moores Cancer Center. The center focuses on genomically-driven therapy as well as precision immunotherapy, especially in rare cancers. Dr. Kurzrock is a global leader in personalized medicine, bringing the first transcriptomic study to the clinic in an international setting spanning five countries (WINTHER), as well as the first study of individually customized combination therapy (IPREDICT). Dr. Kurzrock received her MD from the University of Toronto, Canada. She has over 800 PubMed publications, an H-index of 122, has been named to the lists of most highly cited scientists in the world and the 25 world leaders in precision medicine, and she has a uniquely strong record of competitive funding with more than 100 million dollars in lifetime funding.

Biography
Dr. Kurzrock is a board-certified medical oncologist and a renowned expert in precision medicine. She is known for developing one of the largest and best known Phase I clinical trial programs in the United States while at MD Anderson Cancer Center in Texas. Dr. Kurzrock established the UCSD’s Center for Personalized Cancer Therapy at the Moores Cancer Center. The center focuses on genomically-driven therapy as well as precision immunotherapy, especially in rare cancers. Dr. Kurzrock is a global leader in personalized medicine, bringing the first transcriptomic study to the clinic in an international setting spanning five countries (WINTHER), as well as the first study of individually customized combination therapy (IPREDICT). Dr. Kurzrock received her MD from the University of Toronto, Canada. She has over 800 PubMed publications, an H-index of 122, has been named to the lists of most highly cited scientists in the world and the 25 world leaders in precision medicine, and she has a uniquely strong record of competitive funding with more than 100 million dollars in lifetime funding.

Biography
Charles M. Perou, PhD is currently the Co-Director of the Computational Medicine Program, Faculty Director of the Lineberger Comprehensive Cancer Center (LCCC) Bioinformatics Group, and Co-Leader of the LCCC Breast Cancer Research Program at UNC. He is also a member of the ALLIANCE Breast Committee, and the Executive Steering Committee Member of the Translational Breast Cancer Research Consortium (TBCRC). Dr. Perou co-founded 3 biotechnology companies (Bioclassifier, GeneCentric Therapeutics, and Reveal Genomics), which are broadly focused on using genomic assays coupled to novel therapeutics to make improvements for personalized patient care and ultimately to improve cancer patient survival outcomes. His training history includes a Bachelor's degree in Biology from Bates College, a PhD in Experimental Pathology from the University of Utah, and postdoctoral work in the laboratory of David Botstein (then at Stanford University). He won a number of awards including the European Institute of Oncology Breast Cancer Therapy Award, the Jill Rose Award for Distinguished Biomedical Research from BCRF, the Brinker Award for Scientific Distinction from Komen, the Distinguished Scientist Award from the Association of American Cancer Institutes, and most recently been elected as a Fellow of the AACR (FAACR). He authored more than 450 peer reviewed articles, and has been named an inventor on multiple USA and European patents. Lastly, He has been named a Thomson Reuters Most Highly Cited Researcher in 2014-2022, where his work has received more than 240,000 total citations according to Google Scholar.

Biography
Bruce Quinn is a recognized expert on Medicare policy for innovative technologies. He has helped both large and small companies plan product development and market entry strategies and resolve emerging reimbursement issues efficiently. His policy blog, Discoveries in Health Policy, is distributed to over 500 health policy experts each week.

Biography
Catriona Jamieson is a leading physician scientist who has specialized in myeloproliferative neoplasms (MPNs) and leukemia. She discovered missplicing, RNA hyperediting, and splice isoform switching as mechanisms governing human cancer stem cell maintenance in selective niches. These discoveries have helped to shed light on the underlying mechanisms of cancer and have opened up new avenues for targeted therapies. Dr. Jamieson's contributions to the field of precision medicine include her pivotal role in the rescue and development of the JAK inhibitor fedratinib for the treatment of myelofibrosis. Additionally, she is known for her unwavering dedication to advancing innovative therapies and her outstanding leadership as the director of the Sanford Stem Cell Institute at UCSD and as a co-founder of Impact Biosciences and Aspera Biomedicines.

Biography
Ben George, MD is the William F. Staff Endowed Chair and Associate Professor of Medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin. He also serves as the Medical Director of the Clinical Trials Office at the Froedtert and Medical College of Wisconsin Clinical Cancer Center. Dr. George is a Gastrointestinal Medical Oncologist with a clinical and research focus on Pancreatic Cancer. He has been a faculty member at MCW since 2011.

Biography
Eytan Ruppin has served as a professor of Computer Science Medicine since 1995, conducting computational multidisciplinary research spanning computational neuroscience, natural language processing, machine learning and systems biology. In 2014, he joined the University of Maryland as director of its Center for Cioinformatics and Computational Biology (CBCB). In 2018, he moved to the NCI where he founded and is chief of its Cancer Data Science Lab (CDSL). His research is focused on developing new computational approaches for advancing transcriptomics-based precision oncology. Eytan is a member of the editorial board of Molecular Systems Biology, a fellow of the International Society for Computational Biology (ISCB), a recipient of the NCI Director award and the Delano awards and is a co-founder of a few precision medicine startup companies.

Biography
Dr. Cercek is a board certified medical oncologist specializing in the treatment of patients with gastrointestinal (GI) cancers, particularly colorectal cancer (CRC), appendix cancer, and cholangiocarcinoma. Her research is focused on the development of novel systemic and regional therapies, including approaches based on tumor genomics, with the goal of improving outcomes while minimizing treatment related toxicities. She is the founder and codirector of the Center for Young Onset Colorectal and Gastrointestinal Cancer. This clinic is the first of its kind in the world is dedicated solely to the specific needs of people under 50 who have CRC or other GI cancers.

Biography
Catriona Jamieson is a leading physician scientist who has specialized in myeloproliferative neoplasms (MPNs) and leukemia. She discovered missplicing, RNA hyperediting, and splice isoform switching as mechanisms governing human cancer stem cell maintenance in selective niches. These discoveries have helped to shed light on the underlying mechanisms of cancer and have opened up new avenues for targeted therapies. Dr. Jamieson's contributions to the field of precision medicine include her pivotal role in the rescue and development of the JAK inhibitor fedratinib for the treatment of myelofibrosis. Additionally, she is known for her unwavering dedication to advancing innovative therapies and her outstanding leadership as the director of the Sanford Stem Cell Institute at UCSD and as a co-founder of Impact Biosciences and Aspera Biomedicines.

Biography
Dr. Kurzrock is a boardcertified medical oncologist and a renowned expert in precision medicine. She developed one of the worlds largest Phase I clinical trial programs while at MD Anderson Cancer Center. Dr. Kurzrock also founded the UCSDs Center for Personalized Cancer Therapy, focusing on genomicallydriven therapy as well as precision immunotherapy, especially in rare cancers. Dr. Kurzrock brought the first transcriptomic study to the clinic in an international setting spanning five countries (WINTHER), as well as the first Nof1 study of individually customized combination therapy (IPREDICT). Dr. Kurzrock received her MD from the University of Toronto, Canada. She has 900 PubMed publications, an Hindex of 140, has been named to the lists of most highly cited scientists in the world. She has a uniquely strong record of competitive funding with 100 million dollars in lifetime funding, and has overseen early development of multiple drugs that are now FDA approved.

Biography
Dr. Califano is a pioneer in the field of systems biology and founding chair of the Department of Systems Biology at Columbia University. He has taken innovative approaches to identify drivers of cancer progression and drug resistance at the singlecell level. Rather than focusing on gene mutations, Dr. Califano analyses the complex, tumorspecific cellular networks that determine cancer cell behavior to pinpoint master regulator proteins that are mechanistically responsible for tumorigenesis and tumor cell homeostasis. Dr. Califano and his lab have shown that master regulators represent critical drivers and tumor dependencies, thus establishing them as a bona fide new class of therapeutic targets. Dr. Califano is a fellow of the American Association for the Advancement of Science, the International Society for Computational Biology, and the Institute of Electrical and Electronics Engineers. He is a member of the National Academy of Medicine and a twice recipient of the NCI outstanding investigation award.

Biography
Dr. Sandhya Girish is the Vice President of Clinical Pharmacology Sciences at Gilead Sciences, Inc. Dr. Girish provides strategic and scientific leadership for clinical pharmacology, pharmacometrics and bioanalytical strategies for NMEs spanning both early and late stages of development. Her department is actively involved in a variety of pediatric and adult RD programs across virology, oncology, and inflammation therapeutics areas and is responsible for integrated clinical pharmacology, and MS strategies, including applying MIDD approaches where appropriate. Sandhya has organized technical sessions, workshops and roundtable discussions on therapeutic protein drug interactions, ADCsTDCs, Novel Combinations, Organ Impairment, FIH dosing etc. With support from her team Dr. Girish has successfully led and supported numerous submissions, including but not limited to Herceptin, Perjeta, Kadcyla, TECENTRIQ, POLIVY, Trodelvy, Sunlenca, etc. Sandhya is passionate about combining insights from clinical trials with data from virtual clinical trials, RWD, AIML to accelerate drug development.

Biography
Michael Milburn has over 20 years of executive leadership experience in drug and diagnostic companies including GSK, Plexxikon, Sirtris Pharmaceuticals, and Metablolon. A biotechnology innovator, he has published over 150 scientific articles and is an expert in the development and commercialization of drug and diagnostic products. He started his career in structurebased drug discovery and published the first scientific articles on the crystal structures of p21 ras proteins in the active and inactive state. He developed the first structurebased fragment screening technology and chemistry and published the first scientific articles on this drug discovery methodology. At GeneCentric, Michael leads the effort to bring RNA based diagnostics to the forefront of precision medicine and the next generation of companion diagnostics.

Talk
Advancing Precision Medicine with Novel RNA Companion Diagnostics
GeneCentric develops and commercializes novel RNAbased companion diagnostics to augment shortcomings in more traditional diagnostic testing such as DNA alterations or IHC. While DNA variants have been valuable in precision medicine, they only reflect potential oncogenic activation. In contrast, RNA diagnostics can be derived to reflect actual oncogenic activity and therefore more predictive of therapy.

Biography

Biography
Maggie serves as the Vice President of Marketing for Pharma and Therapeutic Areas at Labcorp with responsibility for leading go-to-market efforts for Early Development and Central Laboratories, Cell and Gene Therapy, Precision Medicine, and Diagnostics for Oncology Specialty Medicine. As a veteran of the genomics industry, she is passionate about delivering innovative, highly differentiated solutions to market that advance precision medicine and improve health outcomes. Maggie has more than two decades of experience in the life sciences and diagnostics industries, and is a graduate of Duke University, where she earned her MS degree in Molecular Cancer Biology and BS degree in Biology.

Biography
Hope S. Rugo, is a Professor of Medicine in the Division of Hematology Oncology at the University of California, San Francisco (UCSF). She is Director of Breast Oncology and Clinical Trials Education at UCSF's Helen Diller Family Comprehensive Cancer Center. Dr. Rugo is an internationally recognized expert in breast cancer. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating tumor DNA as a marker of response and resistance to therapy, neoadjuvant therapy, and safety supportive care. She is a principal investigator of multiple clinical trials and has published widely in medical journals. Dr. Rugo also plays an active role in the Alliance for Clinical Trials in Oncology, the Translational Breast Cancer Research Consortium, ASCO, MASCC, and international guideline committees including NCCN. Dr. Rugo is dedicated to education and mentorship, providing guidance to medical students, residents, and fellows at UCSF and beyond.

Biography
Dr. Adrian Lee is the Pittsburgh Foundation Chair and Director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalized well-being and clinical care. He is also Professor of Pharmacology & Chemical Biology and Human Genetics at UPMC Hillman Cancer Center. Dr. Lee received B.Sc. and Ph.D. degrees in England, and came to San Antonio, Texas for his postdoctoral studies. He was subsequently recruited to Baylor College of Medicine and to the University of Pittsburgh in 2010. The goal of Dr. Lee’s research laboratory is to translate basic cell and molecular research findings into the understanding and treatment of breast cancer. Dr Lee has published over 180 peer reviewed research articles. His laboratory is supported by funding from the NIH, Department of Defense, Susan G. Komen for the Cure, Breast Cancer Research Foundation, and other sources.

Biography
Dr. Grammer is an internationally recognized scientist and successful entrepreneur, having founded and managed AMPEL successfully for over 5 years. Dr. Grammer was elected to the class of 2021 for SIBF (Society of International Business Fellows), an organization of 1,400 individuals in 45 countries worldwide. She was also awarded a Virginia SBIG grant for AMPEL's first investment round. She is a second term board member of Virginia Bio. Before cofounding AMPEL in 2013, Dr. Grammer spent over 20+ years in genomics and managed more than 15 National Institute of Health (NIH) scientific teams and a highly productive NIH laboratory. Dr. Grammer received multiple awards for her team's work comparing genes expressed in patients compared with healthy individuals, including the prestigious NIH Director's Award as well as mentoring awards from the American Association of Immunologists. She has published over 75 articles on her scientific research.

Talk
RNA and Predictive AI Differentiate Benign from Malignant Tumors

Biography
Kathryn A. Phillips founded the UCSF Center for Translational and Policy Research on Precision Medicine over a decade ago. She has published 200 articles in major journals (e.g., JAMA, New England Journal of Medicine, Science, Health Affairs) and has had funding from NIH as a PI for 30 years. Kathryn is the EditorinChief of Health Affairs Scholar; serves on the editorial boards for Health Affairs, Value in Health, JAMA Internal Medicine; is a member of the National Academy of Medicine Roundtable on Genomics; has served on the Board of Directors for GenomeCanada and as an advisor to FDA and CDC; and is a member of ICERs evidence review committee.

Biography
Dr. Tsimberidou is a Professor of Medical Oncology at MD Anderson. She has designed highly innovative clinical trials that have changed the standard of oncology practice. She pioneered the personalized medicine program for advanced cancer that improved patient care and established a model for clinical trials at other institutions, nationally and internationally. She led multiple clinical trials and has published 350 articles. She has been invited to present her work as a keynote speaker at national and international conferences. She has received many awards, including an ASCO Career Development Award. She chaired ASCO's Clinical Research Committee (2016-2017) and she was appointed as a member of other committees. Because of her accomplishments in personalized medicine, she was elected a Fellow of the American Association for the Advancement of Science (FAAAS) and for her contributions to ASCO, she received the designation of Fellow of ASCO (FASCO). She is a Katherine Russell Dixie Distinguished Endowed Professor.

Biography
Lincoln has over 8 years of experience in diagnostic development and a passion for translating genomic science into patient care. In his current role at Foundation Medicine he oversees evidence generation planning and execution for comprehensive genomic profiling assays with a focus on tissueagnostic monitoring. Lincoln most recently led the design and execution of the clinical strategy for a new ctDNA tumor fraction based on his deep scientific and disease biology understanding, translational expertise, and medical knowledge. Prior to joining Foundation Medicine, Lincoln worked at Caris Life Sciences and Health Advances, a boutique life sciences consulting firm, and holds an undergraduate degree in Biology from MIT and a PhD in microbiology and immunobiology from Harvard Medical School.

Biography
Dr. Hatim Husain is a board certified medical oncologist who specializes in lung cancer, genomically oriented targeted therapy, and immunotherapy. He is an Associate Professor at the University ofCalifornia, San Diego. Dr. Husain earned his medical degree from Northwestern University Feinberg School of Medicine. He completed a fellowship in medical oncology at Johns Hopkins University School of Medicine and a residency in internal medicine at the University of Southern California. Dr. Husain is a physician scientist dedicated to understanding the cancer genome and tumor microenvironment and works on strategies to advance meaningful, precision oriented therapies for patients.

Talk
We will discuss the role of circulating tumor DNA serial monitoring and how tumor fraction may improve our ability to call true negative variants and correlate with clinical outcomes.

Biography
Mark has over 20 years of executive and entrepreneurial experience in the rare disease space at multiple venture backed companies. He held positions of increasing responsibility in business development (culminating as VP) at Dyax Corp, which was acquired by Shire for its FDA-approved drugs for hereditary angioedema. He has been a founder, CEO, or Executive Chair of Lotus Tissue Repair (a Third Rock Ventures company acquired by Shire), PellePharm and Molecular Skin Therapeutics (both BridgeBio companies), SeylanMed and Chromaderm (both merged into Dermbiont), NFlection Therapeutics, and Phoenicis Therapeutics. Mark is a board member of SNAPkids, a San Francisco Bay Area non-profit organization, and an advisor to the CureGM1 Foundation.

Talk
Sonodynamic Therapy: Revolutionary Non-Invasive Targeted Cancer Treatment
SonALAsense's sonodynamic therapy (SDT) is a new modality to treat cancer. It uses ultrasound to activate a drug that is selectively taken up by tumors. Clinical data shows that SDT kills brain tumor cells, regresses tumors, and extends survival without any safety concerns.

Biography
Suzanne Garner bringing with her the valuable perspective of an early-stage breast cancer survivor. This personal experience with breast cancer has fueled her passion for patient advocacy and her commitment to improving outcomes for others facing this disease. In her role at Outcomes4Me, Suzanne directs her expertise toward fostering an engaged and empowered patient community. Combining her lived experience with her professional role, Suzanne provides a unique perspective on the patient experience and the evolution of personalized cancer care. A believer in the power of technology, especially artificial intelligence, Suzanne is a champion of using AI to make cancer care more accessible and fair for everyone. She envisions a world where AI bridges the gap in healthcare disparities, offering personalized, accessible, and equitable care solutions for every cancer patient, regardless of their background or circumstances.

Biography
Dr. Rushton is a board-certified pathologist in anatomic and clinical pathology, hematopathology, and molecular genetic pathology with extensive health system leadership. In addition to her active clinical practice with over 13 years of experience, she presently serves as the System Medical Director for Pathology and Laboratory Medicine at Baptist Health System in San Antonio, TX. As the Vice Chief of Staff and Chair of the Quality Committee at the Baptist Medical Center Hospital, she led transformative initiatives around the operationalization of precision oncology testing. She received her medical degree from Baylor College of Medicine, where she also completed fellowships in hematopathology and molecular genetic pathology. Dr. Rushton is also a passionate advocate for physicians and patients, serving in various leadership roles at her county and state medical societies as well as the American Medical Association.

Biography
David W. Craig is an internationally recognized leader in developing and applying novel bioinformatics and genomics tools as well as in translating genomic discoveries from bench to bedside. Craig leads an integrative translational sciences department at City of Hope comprehensive cancer center that focuses on precision measurement, data science and diversity. His team seeks to further improve both translational outcomes as well as the science underpinning the use of precision medicine.Craig collaborates with regulatory agencies, industry partners, researchers and health care professionals to integrate scientific findings and translate potentially practice-changing discoveries into improved patient care and human health. He has spearheaded collaborative computational and data science efforts within large and small research consortiums, including the 1000 Genomes Project and the Bipolar Genome Study. His exceptional expertise has resulted in more than 200 publications, four patents and two founded companies.